First Wave BioPharma, Inc.
Simbols: FWBI
NASDAQ
2.82
USDTirgus cena šodien
-0.2784
P/E koeficients
0.0000
PEG koeficients
5.71M
MRK Cap
- 0.00%
DIV ienesīgums
First Wave BioPharma, Inc. (FWBI) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10.3 | 3.7 | 1.4 | 8.2 | ||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 0.02 | 0 | 0.1 | 0 | ||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-current-assets | 4.49 | 1.2 | 2 | 1176268 | ||||||||||
balance-sheet.row.total-current-assets | 14.82 | 5 | 3.4 | 9.4 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 0.98 | 0.2 | 0.3 | 0.4 | ||||||||||
balance-sheet.row.goodwill | 6.74 | 1.7 | 1.7 | 1.9 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 6.74 | 1.7 | 1.7 | 1.9 | ||||||||||
balance-sheet.row.long-term-investments | 0.09 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.tax-assets | -0.06 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 0.12 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-non-current-assets | 7.86 | 1.9 | 2 | 2.4 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 22.67 | 6.9 | 5.4 | 11.8 | ||||||||||
balance-sheet.row.account-payables | 3.19 | 0.6 | 0.7 | 2.7 | ||||||||||
balance-sheet.row.short-term-debt | 1.41 | 0.7 | 0.7 | 0.7 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 0.69 | 0.1 | 0.2 | 0.3 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 2.58 | 0.8 | 1.1 | 8 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 0.69 | 0.1 | 0.2 | 7.3 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 0.89 | 0.1 | 0.3 | 0.4 | ||||||||||
balance-sheet.row.total-liab | 12.2 | 3.3 | 2.7 | 19.6 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -713.95 | -184.3 | -168.5 | -153.9 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | -1.2 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 724.43 | 187.9 | 171.3 | 147.3 | ||||||||||
balance-sheet.row.total-stockholders-equity | 10.48 | 3.6 | 2.7 | -7.8 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 22.67 | 6.9 | 5.4 | 11.8 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | 10.48 | 3.6 | 2.7 | -7.8 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 22.67 | - | - | - | ||||||||||
Total Investments | 0.09 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-debt | 2.1 | 0.8 | 0.9 | 1 | ||||||||||
balance-sheet.row.net-debt | -8.2 | -2.9 | -0.5 | -7.2 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -15.79 | -15.8 | -14.6 | -58.5 | |||||||||
cash-flows.row.depreciation-and-amortization | 0.03 | 0 | 0 | 0.5 | |||||||||
cash-flows.row.deferred-income-tax | -0.17 | 0.2 | 0 | 3.8 | |||||||||
cash-flows.row.stock-based-compensation | 1.04 | 1 | 0.8 | 1.4 | |||||||||
cash-flows.row.change-in-working-capital | 2.19 | 2.2 | -10.5 | 17.1 | |||||||||
cash-flows.row.account-receivables | 0.09 | 0.1 | -0.1 | 0.6 | |||||||||
cash-flows.row.inventory | 0.75 | 0 | 0.1 | -0.6 | |||||||||
cash-flows.row.account-payables | -0.17 | -0.2 | -2 | 1.4 | |||||||||
cash-flows.row.other-working-capital | 1.51 | 2.3 | -8.5 | 15.7 | |||||||||
cash-flows.row.other-non-cash-items | 0.32 | 0 | 2 | 3.5 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -12.38 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.5 | -0.5 | 0 | -10.3 | |||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.5 | -0.5 | 0 | -10.3 | |||||||||
cash-flows.row.debt-repayment | -0.6 | -0.6 | -0.6 | -507125 | |||||||||
cash-flows.row.common-stock-issued | 9.88 | 15.8 | 23 | 32.7 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 4000000 | |||||||||
cash-flows.row.dividends-paid | 0 | -0.3 | 0 | -4507125 | |||||||||
cash-flows.row.other-financing-activites | 6.04 | 15.4 | -6.6 | 1014262.1 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 15.23 | 15.2 | 15.7 | 44.8 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -0.3 | 0 | |||||||||
cash-flows.row.net-change-in-cash | 2.35 | 2.3 | -6.9 | 2.2 | |||||||||
cash-flows.row.cash-at-end-of-period | 10.37 | 3.7 | 1.4 | 8.2 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 8.02 | 1.4 | 8.2 | 6.1 | |||||||||
cash-flows.row.operating-cash-flow | -12.38 | -12.4 | -22.3 | -32.3 | |||||||||
cash-flows.row.capital-expenditure | -0.5 | -0.5 | 0 | -10.3 | |||||||||
cash-flows.row.free-cash-flow | -12.88 | -12.9 | -22.3 | -42.6 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.cost-of-revenue | 0.08 | 0 | 0.1 | 0.5 | |||||||||
income-statement-row.row.gross-profit | -0.08 | 0 | -0.1 | -0.5 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 5.03 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 10.74 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.01 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 0 | 0 | -0.2 | 0.5 | |||||||||
income-statement-row.row.operating-expenses | 15.76 | 15.7 | 12.7 | 56.7 | |||||||||
income-statement-row.row.cost-and-expenses | 15.77 | 15.8 | 12.7 | 56.7 | |||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.interest-expense | 0.02 | 0 | 0 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.01 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | -0.02 | 0 | -2 | 0.5 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | -0.2 | 0.5 | |||||||||
income-statement-row.row.total-operating-expenses | -0.02 | 0 | -2 | 0.5 | |||||||||
income-statement-row.row.interest-expense | 0.02 | 0 | 0 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 0.03 | 0 | -0.2 | 3.4 | |||||||||
income-statement-row.row.ebitda-caps | -15.74 | - | - | - | |||||||||
income-statement-row.row.operating-income | -15.77 | -15.8 | -12.7 | -59.1 | |||||||||
income-statement-row.row.income-before-tax | -15.79 | -15.8 | -14.6 | -58.5 | |||||||||
income-statement-row.row.income-tax-expense | 0.02 | 0 | 2 | 0.5 | |||||||||
income-statement-row.row.net-income | -15.81 | -15.8 | -16.6 | -59.1 |
Biežāk uzdotie jautājumi
Kas ir First Wave BioPharma, Inc. (FWBI) kopējie aktīvi?
First Wave BioPharma, Inc. (FWBI) kopējie aktīvi ir 6883195.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.000.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -8.250.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.000.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.000.
Kāda ir First Wave BioPharma, Inc. (FWBI) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -15794983.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 826844.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 15741553.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 3711770.000.